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Abbreviations 
 
ABPM: ambulatory blood pressure monitoring 
ACE-inhibitor: angiotensin-converting enzyme inhibitor 
ACTH: adrenocorticotrop hormone  
Aix: augmentation index 
ARB: angiotensin receptor blocker 
AT II:  angiotensin II  
CKD: chronic kidney disease 
DM: diabetes mellitus 
DUAL: patients treated with dual RAAS blockers 
EDTA: ethylenediaminetetraacetic acid 
EO: endogenous ouabain 
ERK: extracellular signal-regulated kinase 
HPLC: high performace liquid chromatography 
HT: hypertension 
MONO: patients treated with ACE inhibitors 
Pro-BNP: pro-brain type natriuretic peptide  
PWV: pulse wave velocity 
RAS: renin-angiotensin-system  
RIA: radio-immunoassay 
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Introduction  
 
The clinical effects of digitalis have been known for more than two centuries in the treatment 
of congestive heart failure. The investigation and function of the sodium- potassium pump 
(Na/K ATP-ase) had a great role in appraisal of the pathomechanism of digitalis. It was 
suspected earlier that an endogen factor modifies the activity of Na/K ATP-ase in the salt-
dependent hypertension and fluid-expansion conditions. In 1990s, many investigators have 
reported extraction of a material from blood and other tissue sources similar to ouabain, and 
its chemical structure is similar to digitalis. This introduction and thesis aimed to give a short 
overview about endogenous digitalis like factors, especially endogenous ouabain, and its role 
in human diseases. 
1.1. Effect of endogenous ouabain 
 
For twenty years endogenous ouabain (EO) is known as a physiologic regulator of the activity 
of sodium/potassium pump (Na+/K+ ATPase) which blocking increases intracellular calcium 
level by the activation of the sodium-calcium exchanger. The increased concentration of 
intracellular calcium causes an enhanced contraction in the heart muscle and vasoconstriction 
in the vascular system. Beyond the classical effects of EO, the digitalis-like factors have 
genomic effects inducing hypertrophy in myocardial and vascular smooth muscle cells due to 
the activation of numerous known intracellular signaling pathways. This activation results in 
hypertension and rigidity of arterial wall. The background of cardiovascular damage in 
diabetes mellitus and chronic kidney disease are not entirely known, the role of EO in 
pathogenesis of this process is also suggested.  Previous studies have shown that EO is mostly 
produced in the adrenal cortex due to the increased level of adrenocorticotrop hormone 
(ACTH) and angiotensin II (AT II), and in addition to sympathetic activation and salt- 
dependent fluid expansion. During physical exercise, the level of EO was increased for a short 
time in both human and dogs; this increase could be reduced by previously receiving beta-
blockers and angiotensin converting enzyme inhibitor (ACE-I). Based on this observation, the 
roles of sympathetic nervous system activation and renin-angiotensin-system (RAS) are 
suggested in the development of enhanced EO secretion. Level of EO was significantly 
increased in untreated patients with hypertension and normotensive offspring of hypertensive 
patients. The level of EO was also raised in patients with primary hyperaldosteronism, 
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Cushing disease, chronic renal failure, congestive heart failure compared to the controls. 
There is little information about correlation between the levels of plasma, urinary EO and the 
parameters of a complex cardiovascular examination in treated human hypertensives with 
comorbidities (diabetes mellitus, chronic kidney disease). Besides this, we have not found 
literature data about relations between levels of EO and markers of early vascular damage 
(arterial stiffness) nevertheless these relations are underlined by experimental data. 
The level of EO is elevated in patients with untreated hypertension, but the levels of EO in 
treated hypertensives, and their associations with different cardiovascular parameters is not 
known. Endogenous ouabain enhances some intracellular signaling pathways, especially ERK 
1/2 pathway, which closely associates with oxidative stress. This process may damage the 
vasculature, which produces atherosclerosis and high blood pressure. In the progression of 
worsen outcome of hypertension, diabetes mellitus and renal disease have a major role of the 
enhanced production of free radical, so that the measurement of this marker is important in 
the detection of complications of these diseases. Oxidative marker, especially the production 
of hydroxyl free radical modified amino acid (ortho-tyrosine) is high-quality marker of this 
process. The EO stimulated oxidative intracellular pathways are known, however there are no 
information about the correlation between the EO secretion and oxidative markers in human. 
According to earlier studies the elevated EO level due to the physical movement were blocked 
with administration of ACE inhibitor and β-blockers.  Effect of ACE inhibitors is known, but 
additive effect of further AT receptor blockers on EO secretion is not identified yet in human.  
The additive effect of AT II inhibitor added to the ACE inhibitor therapy (dual RAS 
blockade) in context to the reduction of EO secretion is not known in human. Results of mono 
and dual RAS blockade on urinary albumin excretion is well known in human, but the 
immuno-unreactive urinary albumin and its correlations with cardiovascular status were not 
studied earlier.  
 
2. Aims 
2.1. Levels of plasma and urinary endogenous ouabain in different study groups, and its 
relations with cardiovascular markers 
 
• Aims of the study were to measure the concentration of plasma and urinary EO in only 
hypertensive patients and hypertensives with other diseases (type 2 diabetes mellitus, 
chronic renal disease). As well as we studied correlation of the measured EO levels 
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and diastolic dysfunction of the patients’ heart, and arterial rigidity, which often 
correlates with these conditions. 
• We also studied the relations between the concentrations of plasma, urinary ortho-
tyrosine -which are relevant markers of production of hydroxyl free radicals- and EO 
levels. 
 
2.2 Effects of Mono and dual RAS blockade on cardiovascular parameters, especially on 
levels of EO and urinary albumins 
  
• In another study we hypothezed that EO production is reduced if the patients are 
treated with dual (ACE-I and AT II inhibitor) RAS blockers compared with mono 
RAS blockers (only ACE inhibitor, which has proved reducing effect on the EO 
production), and we examined their relating effect on the patients’ cardiovascular 
parameters.   
• Our aims were to look for correlations between the levels of EO, urinary albumin and 
cardiovascular parameters in the two groups. 
      
3. Patients and methods 
3.1 Patients 
 
In our first cross-sectional clinical study 41 treated, adult patients were investigated, who 
were divided into 4 groups: (1) group of primary hypertensive, non-diabetic patients without 
chronic kidney disease (HT, N=10); (2) group of hypertensive patients with type 2 diabetes 
mellitus (HT+DM, N=11); (3) group of hypertensive patients with type 2 diabetes mellitus 
and chronic kidney disease (HT+DM+CKD, N=10); (4) group of hypertensive patients with 
chronic kidney disease (HT+CKD, N=10). 
 
In another cross-sectional clinical study 35 adult, hypertensive patients with mild and 
moderate renal failure were investigated. Retrospectively, these patients received either 
mono- or dual blockade of the RAS. In the MONO-group patients were treated with ACE 
inhibitor, (N=20); in the DUAL-group patients were treated with ACE inhibitor plus ARB, 
(N=15) for more than 2 years (median 2.6 years). 
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3.2 Methods 
Most of the laboratory and other cardiovascular methods were similar in the two clinical 
studies, thus the description of methods are summarized below in an integrated form.  
 
3.2.1. Plasma and urinary endogenous ouabain determination 
From all patients 6 ml blood was collected from cubital vein into EDTA tubes between 7-8 
a.m. after at least 40 minutes strict supine position. Then tubes were centrifuged with 3000xg 
within 10 minutes, and plasma was separated and transferred into plastic tubes and stored at -
20oC until assayed. Ten milliliters of urinary samples were taken out of 24-h collected urine 
and were stored at -20oC. Plasma and urinary EO levels were determined by 
radioimmunoassay (RIA) with Ouabain 125I RIA kit (Biotop OY, Medipolis Center, Oulu, 
Finland). All samples were measured in duplicates.  
 
Urinary catecholamine and serum pro-BNP measurements 
The morning urinary catecholamines (epinephrine, norepinephrine and dopamine) were 
measured by BIO-RAD Clinical HPLC System (BIO-RAD Laboratories, Inc., France). 
Briefly, the acidified urinary samples were prepared by Analytical Micro-GuardTM Cartridges 
and 20µl prepared samples were analyzed by HPLC with Model 1340C Electrochemical 
Detector (at 0.55mV). Urinary catecholamine/ creatinine (assessed by Jaffe methods) ratios 
were calculated. The results were corrected with urinary creatitine.  
Serum pro-BNP levels were measured on fully automatized (ElecsysTM 2010) system (Roche 
Diagnostics, Mannheim, Germany), which is an electrochemiluminescent sandwich 
immunoassay using two polyclonal antibodies directed at the NTpBNP molecule. 
 
O-tyrosine measurement  
Briefly, from the 24-hour collected urine or freshly obtained fasting heparinized plasma 
samples, aliquots of 250 µL were taken and handled on ice. One hundred and twenty-five 
microliters of 60% trichloroacetic acid was added to the samples, vortexed, and incubated 30 
minutes on ice to precipitate protein content. To remove the precipitate, samples were then 
centrifuged at 15,000 rpm for 10 minutes in Eppendorf tubes. The supernatant was filtered 
through a 0.2 µm syringe filter (Millipore, Billerica, MA, USA), and 20 µL was injected into 
the manual injector of the high-performance liquid chromatography (HPLC) device. 
The analysis was performed using a Shimadzu Class LC-10 ADVP HPLC system 
(Shimadzu USA Manufacturing, Inc., Canby, OR, USA) equipped with a Shimadzu RF-10 
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AXL fluorescent detector (Shimadzu USA Manufacturing, Inc.). The amino acids (p-, m-, o-
Tyr, Phe) were measured upon their autofluorescence, the Tyr isoforms at 275 nm excitation 
and 305 nm emission wavelengths, while Phe at 258 nm excitation and 288 nm emission 
wavelengths. The analysis was performed using a Licrospher C-18 ODS column, in an 
isocratic run using an aqueous solution of 1% acetic acid and 1% sodium-acetate as the 
mobile phase. External standard calibration and measurement of areas under the curve were 
used to calculate the exact concentrations of the investigated amino acids. 
 
Urinary microalbumin measurements 
Twenty-four hours collected urine samples were vortexed and centrifuged (10 min, 2500xg). 
Supernatants were divided into two portions. One portion was used to detect urinary albumin 
concentration by immunoturbidimetry using a Roche/Hitachi 812 Modular P analyser 
(sensitivity: 3 mg/l, intra-assay precision 1.3% and 1.7%, inter-assay precision 4.3% and 2.6% 
respectively, linearity: 3-3000 mg/l, Roche Diagnostics GmbH, Mannheim, Germany). The 
other portion was used for high performance liquid chromatography (HPLC) analysis 
straightaway or in a few days (after storage at -20°C). For HPLC measurements the FDA 
approved AccuminTM kit (Accumin Diagnostics Inc., New York, NY, USA) was used.  
Amount of immuno-unreactive albumin was calculated as the difference of HPLC and 
immunoturbidimetry measured urinary albumin.  
 
 
Echocardiography, echo-tracking examination of arterial stiffness and ABPM 
Echocardiograms were recorded with an Aloka SSD 5500 (Aloka, Aloka Co. Ltd, Tokyo) 
ultrasound imaging system equipped with a 3.5 MHz transducer. All patients were assessed 
by the same cardiologist and examined within one hour (between 7.30-8.30 a.m.) after EO 
samples collecting and ABPM taking off. Before echocardiography and echo-tracking all 
patients were supine position at least for 5 minutes. Operators were blinded to the status of the 
patients. The measurements of echocardiography were assessed according to the American 
Society of Echocardiography guidelines. Arterial stiffness parameters as the β stiffness index 
(β), pulse wave velocity (PWV), and augmentation index (Aix) were assessed by the 
characteristics of pulse wave intensity using echo-tracking system (Aloka SSD-5500, Aloka 
Co. Ltd, Tokyo) with a 10 MHz linear array probe. We used the right common carotid arterial 
diameter change waveforms to obtain pressure waveforms noninvasively. The peak and 
bottom values of a diameter change waveform were calibrated using systolic and diastolic 
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pressure measured with a cuff-type manometer applied to the upper arm, and the diameter 
change waveform was used as a blood pressure waveform.  
The ambulatory blood pressure monitoring was done with ABPM-04 (Meditech, Meditech 
Ltd., Budapest, Hungary) based on validated oscillometric technique. During a 24-h 
monitoring period the blood pressure was registered in 15 minute intervals in daytime (8 a.m. 
to 10 p.m.) and 30 minute intervals during nighttime (10 p.m. to 8 a.m.). The results (mean 
arterial blood pressure, hypertensive time index) of blood pressure monitoring were analyzed 
by the proprietary software of ABPM-04. 
 
Statistical analyses 
The data are expressed as mean values ± standard deviation, or as median values and 
interquartile range depending on the distribution. Distribution of the variables was analyzed 
using Kolmogorov-Smirnov test. Normally distributed variables were compared using two 
samples T-test, while non-normal distributed variables were compared with Mann Whitney U 
test. Pro-BNP levels were normalized by a logarithmic transformation in order to depict 
correlations with pro-BNP. Difference of parameters groups was analyzed with univariate 
general linear model, adjusted for age or age, HbA1c, LVESD, LVESV, and ejection fraction 
of heart. The non-continuous parameters were analyzed by χ 2-test. The correlations between 
variables were analyzed using Pearson’s (in cases of normally distributed variables) and 
Spearmann’s (non-normally distributed variables) correlations. The statistical analyses were 
made by SPSS 13.0 (SPSS Inc, Chicago, IL, USA) and two tailed P value of <0.05 was 
considered statistically significant. 
 
1.1.1. Results 
 
In our first study the highest level of plasma endogenous ouabain (19.7 ± 9.5 pmol/l) was 
measured in hypertensive patients with diabetes mellitus and chronic kidney disease, which 
was significantly higher than in HT+CKD group (after adjusting for age). The level of urinary 
EO and EO clearance did not show significant difference between the groups.  
The EO clearance in HT group (31.2%) was significantly higher in the HT (14.3%) and 
HT+DM (11.5%) groups. There were no differences between groups in daytime, nighttime 
systolic, diastolic, mean arterial blood pressure and their hypertensive time index as well as 
diurnal index. According to the mean blood pressures of the groups, the patients were well-
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treated in this study. The mean parameters of echocardiography and echo-tracking arterial 
stiffness were not shown differences between groups. 
 
Plasma level of EO showed several significant correlations mainly with parameters of the 
nighttime blood pressure as nighttime systolic (p=0.014), diastolic (p=0.029), mean arterial 
blood pressure (p=0.009) and their hypertensive time indicis in the whole population. 
Relationship between these parameters may due to the increased nighttime/morning 
sympathetic tone because the levels of urinary catecholamines (norepinephrine) correlated 
with EO level (R=0.396, p=0.011). In the analysis of data of whole population we found some 
significant association between the level of urinary EO and carotid artery PWV (p=0.023) and 
β-stiffness (p=0.009).  
 
The nighttime mean arterial blood pressure independently correlated with the level of plasma 
endogenous ouabain (p=0.004), while independent predictor of the β-stiffness of carotid 
artery was the urinary endogenous ouabain (p=0.011).    
Fractional excretion of EO was higher in HT+DM+CKD and HT+CKD groups than other 
groups, and grade of fractional excretion showed significant correlation with nighttime mean 
arterial blood pressure (R=-0.361, p=0.029) as well as the end-systolic (R=0.345, p=0.029) 
and diastolic (R=0.356, p=0.024) diameters of the heart.  
The fractional excretion of EO also showed close relations with pulse wave velocity and β-
stiffness of carotid artery in the HT+DM group. 
In the HT+DM+CKD group the plasma EO and diastolic dysfunction of the heart (R=-0.665, 
p=0.036), as well as some nighttime blood pressure parameters were associated. 
The urinary level of o-tyr is not differed in groups, but the level of plasma o-tyr was 
significantly higher the in the HT+DM+CKD and HT+CKD groups than HT group (p=0.028 
and p=0.04, respectively). We have not found correlations between plasma o-tyr and markers 
of cardiovascular disease in the whole population or in the groups. Levels of o-tyr did not 
show any correlations with levels of EO. Level of o-tyr correlated with the markers of renal 
function only. 
 
In our second study we have found that the long-term dual RAS blockade did not reduce 
more the levels of urinary and plasma EO, compared to the mono RAS blockade. In the 
cardiovascular parameters the groups were not different, except of some echocardiographic 
parameters (ejection fraction of heart, end-systolic diameter and volume). 
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We have found difference between the pro-BNP levels of the groups only. 
The plasma level of EO correlated with some nighttime blood pressure values, as systolic 
(R=0.512, p=0.049) or mean arterial blood pressure (R=0.541, p=0.038) in the MONO-group. 
Also, the urinary EO level associated with pulse wave velocity (R=0.621, p=0.005) and β-
stiffness (R=0.681, p=0.001) of carotid artery in the MONO-group. In the DUAL-group, these 
correlations were not found. 
Regarding the urinary albumins we have explored that the immuno-unreactive urinary 
albumin correlated with diastolic dysfunction marker of the heart (R=-0.492, p=0.028), 
diurnal index of diastolic blood pressure (R=-0.540, p=0.014) in the MONO-group; however 
the immuno-unreactive albumin correlated with only the level of plasma EO (p=0.014) in the 
DUAL-group.    
   
1.1.2. Discussion 
 
Association of EO levels and blood pressure parameters have known for a long time in 
untreated hypertensives, but the relationships of EO levels with the parameters of a complex 
cardiovascular measurement in treated patients with hypertension are not studied. 
In our study the samples collection, echocardiography, and echo-tracking measurements were 
completed in a short time (between 7.30 - 8.30 a.m.). Thus, we tried to eliminate the 
inaccuracy from the circadian variation of EO (which is not known), and so the levels of 
plasma EO strongly mirror the patient’s current (night and early morning) cardiovascular 
status. The pathophysiological abnormalities of this period especially nighttime and morning 
hypertension are major risk factors for acute cardiovascular diseases.  
In our first study the level of EO was highest in HT+DM+CKD group. This result is in 
agreement with results of earlier investigations which suggest that more comorbidities 
potentially associate with higher level of EO.  
The level of plasma EO in healthy individuals was 9-12 pmol/L, assessed previously by the 
same method as we used in hypertensives. In our study the average level of plasma EO was 
14.7 ± 5.7 pmol/L, nevertheless our patients were treated with RAAS blockers and/or β-
blockers. In our study the levels of EO was lower than in some studies in literature using  
other immunoassay methods  which are not comparable with our results because of using 
different antibody and methods. 
26 
 
According to our results the level of endogenous ouabain associated with nighttime blood 
pressures suggesting possible role of endogenous ouabain in the pathogenesis of impaired 
diurnal rhythm of blood pressure and nighttime blood pressure.  
Fractional excretion of EO was significantly higher in groups including patients with chronic 
kidney diseases than others. The EO fractional excretion is less than 2% in healthy men and in 
our patients with hypertension its levels were 11.5 – 31.2 %. This observation may underline 
the role of kidney in regulation of EO level.  
Endogenous ouabain may therefore take part in the development of hypertension through 
increased sympathetic tone, direct prohypertrophic effects on myocytes of heart and arteries. 
These processes can lead to cardiac hypertrophy in vivo. This thesis is emphasized with our 
results in which the level of EO associates with urinary catecholamine level. 
In our study we have found association between left ventricular diastolic dysfunction (E/A) 
and level of plasma EO in HT+DM+CKD group. Similar correlation was proved within 
patients with end stage kidney disease suggesting that the prolonged elevated level of plasma 
EO may have a role in the development of ventricular hypertrophy. 
Long-time effects of endogenous digitalis like factors contribute to the arterial rigidity, which 
explains the correlation of EO levels and arterial stiffness markers in our study.   
Changed excretion of EO play role in the formation of arterial stiffness, because of the 
independent predictor of carotid artery β-stiffness was urinary EO in the whole population. 
This could be a new component between the decreased renal function and arterial stiffness. 
According to our results, the level of EO is a useful marker for the prediction of the severity 
of subclinical organ damage in patients with hypertension.  
In the literature some studies found significant correlations between oxidative stress 
markers and cardiovascular parameters. However, it also known that several medications (e.g. 
AT II receptor blocker, alpha and beta-blocker) decrease the levels of oxidative markers in 
hypertensive patients. The endogenous digitalis like factors regulate the intracellular free 
radical production so we supposed that EO levels and hydroxyl free radical material (o-tyr) 
also correlates with together. In our investigation we have not found any correlation between 
the levels plasma and urinary o-tyr and EO neither in the whole population, nor in the groups. 
In a previous study the level of urinary o-tyr was higher in the patients with diabetes mellitus 
and kidney disease than in healthy controls. In this study the relations between o-tyr level and 
cardiovascular markers were not assessed. In our analysis of data we did not find direct 
relationship between the levels plasma and urinary o-tyr and blood pressure as well as 
echocardiographic, stiffness markers of patients neither in the whole population, nor in the 
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groups. Plasma o-tyr showed correlation with renal function only, which underlines our 
earlier hypothesis that the main regulator of o-tyr may be the kidney. We could not detect a 
direct correlation between level of EO and marker of oxidative stress. The explanation of this 
missing association may be due to renal excretion of o-tyr and to the treatment of the patients 
and the presence of diabetes (in some groups). 
 
The therapy with RAS blocking drugs have been used for some decades to reduce the blood 
pressure, grade of albuminuria and other clinical and subclinical organ damage. Several 
multicenter, randomized studies proved that beneficial effects of dual RAS blockade on 
cardiovascular morbidity, mortality and severity of the subclinical organ damage opposite to 
the mono RAS blockade. In our second study we also compare the results of long-term mono 
and dual RAS blockade on cardiovascular markers, especially focus on immuno-unreactive 
urinary albumin and levels of EO.  Level of plasma and urinary EO (as a new marker in the 
assessment of cardiovascular status) were similar in the two groups. Level of EO correlated 
with nighttime blood pressure as well arterial stiffness parameters in the MONO-group only.  
We have found no difference between the two groups in regarding blood pressure and arterial 
stiffness parameters. Left ventricular status and ejection fraction significantly better in the 
DUAL-group than in the MONO-group, the level of pro-BNP was significantly lower in the 
dual-group, which can refer a enhanced cardiac outcome. The differences between 
echocardiographic parameters could be not explained by different sympathetic activity and its 
suppressions because the excreted levels of catecholamine and β-blocker therapy were 
similar.  Our observation may suggest that although the dual blockade did not lead to lower 
levels of EO, but may decrease the intracellular pathway activity which leads to ventricular 
remodelling. One may suppose, that dual RAS blockade is more effective, than mono 
blockade to preserve lower stiffness of arteries, but according to the literature dual RAS 
blockade compared to the mono blockade does not decrease the risk of cardiovascular 
mortality. 
 
Exact detection of urinary albumin is important for the appropriate treatment in several 
diseases. Based on the different measurement methods, urinary albumin exists in 
immunoreactive and immuno-unreactive form. The recently developed high performance 
liquid chromatography (HPLC) assay measures the total (immunoreactive plus immuno-
unreactive) urinary albumin, whereas the conventional immuno-based methods 
(radioimmunoassay, immunoturbidimetry, immunonephelometry) measure immunoreactive 
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albumin only. In our other study we measured the level of both type urinary albumin and their 
correlations in patients with use of mono and dual RAS blockers.  Some previously published 
studies show significant associations between the level of urinary immunoreactive albumin 
and markers of cardiovascular diseases, but there is little information about the level of 
urinary immuno-unreactive albumin. 
Our main findings of assessment were that the level of urinary albumin was higher assessing 
by HPLC than immunoturbidimetry and the cardiovascular parameters (blood pressure 
parameters, diastolic dysfunction of heart) correlated with the grade of albuminuria 
determined by HPLC in the MONO-group, but in the DUAL-group EO was the only one, 
which correlated with the urinary total and immune-unreactive albumins. None of these 
parameters correlated with the immunoreactive urinary albumin.  
In our study the urinary level of albumin was in the near normalbuminuric range which shows 
that the therapy of patients was appropriate and the greater part of total excreted urinary 
albumin remained immuno-unreactive. The exact nature and formation of immuno-unreactive 
albumin is not known. 
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LIST OF PHD THESIS 
1. Measurement of EO levels is useful markers of the damage of cardiovascular status in 
treated hypertensives, and in hypertensives with comorbidity. 
2. Level of plasma EO is higher in hypertensives with comorbidity (diabetes mellitus and 
renal failure) 
3. Level of EO is correlated with arterial stiffness parameters. 
4. Level of EO correlates with nighttime blood pressure, possibly across by increased 
sympathetic activity. 
5. The hydroxyl free radical marker, o-tyr is not associated with levels of EO in patients with 
treated hypertension. 
6. Kidney is the main regulator of the plasma level of o-tyr. 
7. ARBs with ACE-inhibitors (DUAL RAS blockade) do not decrease more the levels of 
plasma and urinary of EO than ACE-inhibitors alone.      
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